Shattuck Labs

Historical price data

Shattuck Labs is a public biotech company focused on developing novel DR3-targeting antibodies to treat inflammatory diseases, with a primary focus on Inflammatory Bowel Disease (IBD). Its lead program, SL-325, is in Phase 2 development and represents the first clinical-stage DR3 blocking antibody, which the company believes offers potential advantages over competing TL1A-targeting therapies. The company's strategy is built on the scientific premise that blocking the receptor (DR3) rather than the ligand (TL1A) may lead to superior efficacy and reduced immunogenicity. Shattuck is headquartered in the United States with R&D operations in Durham, North Carolina, and a corporate office in Austin, Texas.

Platform for engineering high-affinity, Fc-silenced monoclonal and bispecific antibodies that target and block the Death Receptor 3 (DR3), aiming to inhibit the TL1A/DR3 inflammatory signaling pathway with potentially superior efficacy and reduced immunogenicity compared to ligand-targeting approaches.

6 drugs in pipeline

Main competitors are large pharma companies (Pfizer, Sanofi, Roche) with TL1A-blocking antibodies already in Phase 3 trials for IBD. Shattuck's differentiation is its receptor-targeting approach, which it hypothesizes will yield better efficacy and lower immunogenicity by avoiding serum immune complex formation.